ARTICLE | Clinical News
New data show survival benefit of Biogen's Spinraza
January 14, 2017 1:21 AM UTC
Newly released data showed that Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) met a second primary endpoint of the Phase III ENDEAR study to treat spinal muscular atrophy. The therapy significantly reduced risk of death or permanent ventilation at an end of study analysis.
FDA approved Spinraza last month to treat SMA. It is the first drug approved in the indication (see BioCentury Extra, Dec. 23, 2016)...
BCIQ Target Profiles